Developing breakthrough therapies involves significant time, money, and uncertainty, and requires strong evidence-generation to prove value. Real-world data (RWD) from EHRs can help pharmaceutical and medical device companies inform development strategy and alleviate some of these pressures as they seek to bring products to market and prove their efficacy.
However, not all EHR datasets are created equal. To power critical studies, researchers need access to EHR data with depth, scale, timeliness, and completeness to enable the use of precise inclusion/exclusion criteria among large, highly representative populations, and to understand the full clinical context surrounding treatment use.
In honor of World Heart Day on September 29, join speakers from Truveta, Reprieve Cardiovascular, The Permanente Medical Group, and Stanford Heart Health Tech Center as they discuss how Truveta Data is being used to drive product innovation for acute heart failure.
Dr. Ryan Ahern is the Chief Medical Officer of Truveta with more than a decade of experience in healthcare data and clinical research. At Truveta, Ryan leads the Life Science Partner team which focuses on developing new partnerships and ensuring those partners are successful in their research. He is currently a Clinical Assistant Professor of Medicine at the University of Washington School of Medicine and practices at Harborview Medical Center, Seattle’s large county hospital. Prior to this, he trained in internal medicine at the Massachusetts General Hospital and has served as a Clinical Assistant Professor of Medicine at Weill Cornell Medical Center and New York Presbyterian; attending physician at Massachusetts General Hospital and instructor at Harvard Medical School.
Mark has been CEO of Reprieve Cardiovascular, a startup in the Acute Heart Failure space, since May 2021. Prior to joining Reprieve, Mark spent 16 years with Medtronic in various leadership positions. Most recently, Mark served as the VP & General Manager of Medtronic’s Peripheral Vascular Business. He also held several leadership roles in Strategy & Business Development, Corporate Development, and Sales Leadership across Medtronic’s Cardiovascular and Spine businesses. Mark graduated with a BSB in Management Information Systems from the University of Minnesota Carlson School of Business and an MBA from the University of Michigan.
Andrew P. Ambrosy, MD is a practicing non-invasive cardiologist at Kaiser Permanente San Francisco Medical Center and a clinician-investigator at Kaiser Permanente Northern California (KPNC) –Division of Research. He is also the KPNC Regional Assistant Medical Director of the Clinical Trials Program and supports site-based research for all therapeutic areas across 21 medical centers and more than 260 freestanding clinics. Dr. Ambrosy previously completed his clinical training in cardiovascular medicine and a dedicated research fellowship at Duke University Medical Center/Duke Clinical Research Institute. He is currently the Principal Investigator (PI), Co-PI, or Co-Investigator (Co-I) on several competitive grants and his research is supported through diverse funding sources including the NHLBI, The Permanente Medical Group, and industry sponsors.
Alex Sandhu, MD, MS, is a heart failure cardiologist and health services researcher. He graduated from the seven-year combined BA-MD program at Northwestern Feinberg School of Medicine before completing his training in internal medicine, cardiology, and advanced heart failure & transplant at Stanford University.
He also completed a post-doctoral fellowship in health services research at the Palo Alto VA and Stanford's Center for Health Policy/Primary Care and Outcomes Research. His research program focuses on cardiovascular outcomes using routinely collected healthcare data, health economics, and the implementation of high-value care strategies. He is Director of the AHA-funded Stanford Heart Health Tech Center and co-directs the Palo Alto VA Cardiovascular Outcomes Research Group.